Form 4: Tarsus Pharmaceuticals Executive Acquires Stock Options and Restricted Stock Units

Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• Aziz Mottiwala, the Chief Commercial Officer of Tarsus Pharmaceuticals, filed a Form 4 with the SEC.
• The filing reports the acquisition of 33,691 stock options with an exercise price of $44.54 on March 5, 2025.
• These options vest over four years, starting March 5, 2026, with 25% vesting initially and the remainder vesting monthly over the subsequent three years, contingent upon continuous service.
• Mottiwala also acquired 22,098 restricted stock units (RSUs) on March 5, 2025.
• These RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to continuous service.
• Each RSU represents the right to receive one share of Tarsus Pharmaceuticals' common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, incentivizing long-term commitment. There are no immediate negative implications.

Positives

• The acquisition of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize long-term commitment and performance.

Industry Context

Stock options and RSUs are common forms of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with company performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Vesting schedules of four years are typical to ensure long-term commitment.
• Companies like Alcon and Bausch + Lomb also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates